Last reviewed · How we verify
Tazarotene Foam without irradiation
At a glance
| Generic name | Tazarotene Foam without irradiation |
|---|---|
| Sponsor | Stiefel, a GSK Company |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Potential of Tazarotene Foam to Cause a Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers (PHASE1)
- A Study to Evaluate the Potential of Tazarotene Foam to Cause an Allergic Reaction When Applied to the Skin and Exposed to Light on Healthy Volunteers. (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tazarotene Foam without irradiation CI brief — competitive landscape report
- Tazarotene Foam without irradiation updates RSS · CI watch RSS
- Stiefel, a GSK Company portfolio CI